11:23 AM EST - Medicenna Therapeutics Corp : Announces that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,542,312 titled “IL-2 Superagonists in Combination with Anti-PD-1.” The patent provides intellectual property protection for methods of treating cancer with an IL-2 Superkine such as MDNA11 and a PD1, PDL1 or CTLA-4 checkpoint inhibitor in combination, as planned in the on-going ABILITY clinical trial, or as a single agent using our BiSKIT™ (Bifunctional SuperKine for ImmunoTherapy) platform. The patent’s term extends into at least 2039 without accounting for any potential extensions. Medicenna Therapeutics Corp
shares T.MDNA are trading -$0.02 at $0.74.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=MDNA%3ACA&qmodStoryID=6295341256815028
